We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bausch Health Cos | NYSE:VRX | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 23.40 | 0.00 | 01:00:00 |
From May 2019 to May 2024
Valeant Pharmaceuticals International Inc. (VRX.T) and Bill Ackman's Pershing Square have filed a complaint with the Securities and Exchange Commission over claims that Allergan has been misleading investors by making false and misleading statements about Valeant, CNBC reported Monday.
Specifically, Valeant is objecting to Allergan claims that Valeant has stagnant or declining sales in its Bausch and Lomb business unit, CNBC said.
Robert Khuzami, former head of enforcement of the SEC, is leading the effort for Valeant and Pershing Square, the report said, and separately they have gone to regulators in Quebec to file complaints.
Full story at www.cnbc.com
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Valeant Pharma Chart |
1 Month Valeant Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
